Fordadistrogene Movaparvovec Fails to Improve Functional Outcomes in Duchenne Muscular Dystrophy: Insights from the Phase 3 CIFFREO Trial
Posted inNeurology news Pediatrics

Fordadistrogene Movaparvovec Fails to Improve Functional Outcomes in Duchenne Muscular Dystrophy: Insights from the Phase 3 CIFFREO Trial

The Phase 3 CIFFREO trial found that the gene therapy fordadistrogene movaparvovec did not significantly improve motor function in boys with Duchenne muscular dystrophy compared to placebo, leading to the discontinuation of its clinical development due to a negative benefit-risk profile.
Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis
Posted inCardiology Internal Medicine news

Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis

This large retrospective study of 820 patients reveals that restrictive ventricular physiology is the most common phenotype in cardiac amyloidosis. While preserved LV function offers better initial survival, the rate of progression to restriction is high, emphasizing the need for early clinical detection.
The Psychological Burden of Watchful Waiting: Anxiety and Depression Linked to Increased Rupture Risk and Mortality in Unruptured Intracranial Aneurysms
Posted inNeurology news Psychiatry

The Psychological Burden of Watchful Waiting: Anxiety and Depression Linked to Increased Rupture Risk and Mortality in Unruptured Intracranial Aneurysms

A large-scale retrospective study reveals that anxiety and depression following the diagnosis of unruptured intracranial aneurysms significantly increase the risk of rupture and all-cause mortality, suggesting that integrated psychiatric assessment is a critical component of neurovascular management.